[{"id":"8da9df0c-215f-464f-b7e6-4299e8415fe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759588","created_at":"2021-01-18T13:31:56.704Z","updated_at":"2024-07-02T16:35:58.169Z","phase":"Phase 1b","brief_title":"GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer","source_id_and_acronym":"NCT02759588","lead_sponsor":"Genelux Corporation","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-01-05"}]